Abbott’s Amplatzer Talisman PFO Occluder System Launched in Europe

September 7, 2022—Abbott announced the European launch of its Amplatzer Talisman patent foramen ovale (PFO) occlusion system to treat patients with a PFO who have experienced a stroke and are at risk of having another.

Matthew Daniels, MBBChir, honorary consultant cardiologist in Manchester, United Kingdom, completed the first European procedure with the Talisman system.

Dr. Daniels commented in Abbott’s press release, “Guidelines from industry organizations and clinical trial data continue to reinforce the benefits of PFO closure for people who have had a PFO-associated stroke. We’re excited that physicians around Europe now have access to the Talisman device to help reduce patients’ risk and worry of experiencing another stroke.”

According to the company, the Amplatzer Talisman system builds off the company’s Amplatzer PFO occluder that physicians had to attach to the delivery cable before performing the implant procedure.

Now, the Talisman occluder comes preassembled to the Amplatzer Trevisio delivery cable, reducing preparation time ahead of the procedure and making it easier to use. The Talisman system accommodates a wide range of patient anatomies and an updated 30-mm occluder size optimizes how it fits in the heart.

The Talisman device is fully recapturable and repositionable so physicians can easily make adjustments for accurate placement, noted Abbott.